Home › Major Depressive Disorder › Pennsylvania › Allentown
Major Depressive Disorder clinical trials in Allentown, PA
6 studies for Major Depressive Disorder are looking for participants at sites in and around Allentown (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
RecruitingPhase 2
- Seaport Investigator Site, Allentown
A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
RecruitingPhase 2
- Draig Clinical Site, Allentown
Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
RecruitingPhase 2
- Lehigh Center for Clinical Research, Allentown
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
RecruitingPhase 3
- Lehigh Center For Clinical Research, Allentown
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
RecruitingPhase 2
- Lehigh Center for Clinical Research, Allentown
Study of ALTO-300 in MDD
RecruitingPhase 2
- Site 216, Allentown
Major Depressive Disorder trials in other cities
- New York City, NY36 studies
- Boston, MA31 studies
- Atlanta, GA25 studies
- Philadelphia, PA23 studies
- Orlando, FL19 studies
- Miami, FL18 studies
- Chicago, IL17 studies
- Tampa, FL17 studies
- San Diego, CA16 studies
- Houston, TX16 studies
- Little Rock, AR14 studies
- Austin, TX13 studies
Other studies in Allentown
- Non-Small Cell Lung Cancer14 studies
- Breast Cancer10 studies
- Acute Myeloid Leukemia8 studies
- Colorectal Cancer7 studies
- Lung Cancer7 studies
- Melanoma6 studies
- Cancer (all types)6 studies
- Coronary Artery Disease5 studies
- Burkitt Lymphoma5 studies
- Ovarian Cancer5 studies
- Colon Cancer5 studies
- Rectal Cancer5 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.